Contact Us and People

FullSizeRender

Sherif Hanafy Mahmoud, BSc(Pharm), MSc, PhD

Clinical Assistant Professor

Pharmacy and Pharmaceutical Sciences

About Me

Education

Ph.D., Pharmacokinetics, University of Alberta, Edmonton, Alberta (2010)

Master of Science, Clinical Pharmacy, Ain Shams University, Cairo, Egypt (2005)

Bachelor of Science, Pharmacy, Ain Shams University, Cairo, Egypt (2000)


Clinical Practice

Neurosciences Intensive Care Unit, University of Alberta Hospital, Edmonton, Alberta


Recent Awards

Teaching Excellence Award, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (2016)

Preceptor Recognition Award, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (2016) 


Research

Areas of Interest: Neurocritical Care; Subarachnoid Hemorrhage; Antiepileptic Drugs; Clinical Pharmacokinetics; Epilepsy

Overall research goal: 

My main research goal is to turn observations from benchside and bedside into clinical practice protocols that potentially will improve the outcome in patients with neurological emergencies (subarachnoid hemorrhage, intracerebral hemorrhage, ischemic stroke, traumatic brain injury and status epilepticus) and patients with epilepsy.

I. Subarachnoid Hemorrhage

Subarachnoid hemorrhage (SAH) is a neurological emergency characterized by the extravasation of blood into the subarachnoid space. Although SAH accounts for 5% of all strokes, given the relatively younger age at onset, it has a significant burden on productive-life years. The average mortality rate for SAH has been reported to range from 30-50%, with a significant proportion of survivors left with disability. Neurological and medical complications are common after SAH and contribute significantly to the overall prognosis. The goal of this research is pharmacotherapy optimization of existing therapies and translation of new therapeutics in SAH for the sake of preventing those complications and improving patient outcomes. 

II. Antiepileptic Drugs

Focus on pharmacotherapy optimization of antiepileptic drugs (AEDs) in seizures and epilepsy patients with superimposing comorbidities such as patients undergoing renal replacement therapies. 

III. Altered pharmacokinetics and pharmacodynamics of drugs in critically ill



Teaching

PHARM 417: Neurology

PHARM 489: Seminars in Therapeutics and Professional Practice

PHARM 503: Advanced Pharmacotherapy

PHARM 523: Advanced Pharmacotherapy - Part I

PHARM 532: Patient Assessment

PHARM 533: Advanced Pharmacotherapy - Part II